Platelets and COVID-19: Inflammation, Hyperactivation and Additional Questions
UMass Chan Affiliations
Department of Medicine, Division of Cardiovascular MedicineDocument Type
EditorialPublication Date
2020-11-06Keywords
thrombosisCOVID-19
platelets
inflammation
UMCCTS funding
Biological Factors
Cardiovascular Diseases
Cardiovascular System
Hemic and Immune Systems
Immunology and Infectious Disease
Infectious Disease
Microbiology
Pathological Conditions, Signs and Symptoms
Virus Diseases
Metadata
Show full item recordAbstract
The mechanisms underlining thrombosis in COVID-19 patients are not known and likely due to multiple processes including inflammation, oxygen demand injury, and plaque rupture triggered by the infection. Platelets mediate thrombotic vascular occlusion but are also increasingly recognized to have immunomodulatory activity. Several of our recent studies have characterized the role of viral infections in cardiac disease. Although robust data on the scope of acute myocardial infarction in COVID-19 are not yet available, myocardial infarction contributed to in-hospital mortality during previous severe acute respiratory syndrome/coronavirus epidemics. A recent study has also demonstrated that influenza and other respiratory viruses increase the incidence of acute myocardial infarction particularly in the first 7 days post-infection, suggesting that platelets may be directly involved in mediating an immune response but, when dysregulated, can also lead to thrombotic vascular occlusion.Source
Koupenova M, Freedman JE. Platelets and COVID-19: Inflammation, Hyperactivation and Additional Questions. Circ Res. 2020 Nov 6;127(11):1419-1421. doi: 10.1161/CIRCRESAHA.120.318218. Epub 2020 Nov 5. PMID: 33151798; PMCID: PMC7641185. Link to article on publisher's site
DOI
10.1161/CIRCRESAHA.120.318218Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27352PubMed ID
33151798Related Resources
ae974a485f413a2113503eed53cd6c53
10.1161/CIRCRESAHA.120.318218